Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity[J]. Cancer, 1973, 32 (2): 302-314.
[2]
Ivona Klimtová. Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits[J]. Hum Exp toxicol, 2002, 21(12): 649-657.
[3]
Dragojevic-Simic VM, Dobric SL, Bokonjic DR, et al. Amifostine protection against doxorubicin cardiotoxicity in rats[J]. Anticancer Drugs, 2004, 15(2): 169-178.
[4]
Aupperle H, Garbade J, Schubert A, et al. Effects of autologous stem cells on immunohistochemical patterns and gene expression of metalloproteinases and their tissue inhibitors in doxorubicin cardiomyopathy in a rabbit model[J]. Vet Pathol, 2007, 44(4): 494-503.
[5]
Kawada T, Yamazaki T, Akiyama T, et al. Chronic adriamycin treatment impairs myocardial interstitial neuronal release of norepinephrine and epinephrine[J]. J Cardiovasc Pharmacol, 2000, 36(Suppl 2): 31-34.
[6]
Barcin C, Kursaklioglu H, Safali M, et al. Effect of octreotide in the prevention of doxorubicin cardiotoxicity[J]. Anadolu Kardiyol Derg, 2005, 5(1): 18-23.
[7]
Aiken MJ, Suhag V, Garcia CA, et al. Doxorubicin-induced cardiac toxicity and cardiac rest gated blood pool imaging[J]. Clin Nucl Med, 2009, 34(11): 762-767.
[8]
Kim SY, Kim SJ, Kim BJ, et al. Doxorubicin-induced reactive oxygen species generation and intracellular Ca？2+ increase are reciprocally modulated in rat cardiomyocytes[J]. Exp Mol Med, 2006, 38(5): 535-545.
[9]
Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2005, 23(12): 2629-2636.
[10]
Adamcova M, Simunek T, Kaiserova H, et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity[J]. Toxicology, 2007, 237(1-3): 218-228.
[11]
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002, 347(3): 161-167.
[12]
Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management[J]. Circulation, 2004, 109(25): 3122-3131.
